BioLife Solutions Inc. (BLFS)

16.11
0.56 3.40
NASDAQ : Health Technology
Prev Close 16.67
Open 16.58
Day Low/High 16.08 / 16.92
52 Wk Low/High 9.15 / 22.44
Volume 40.89K
Avg Volume 185.30K
Exchange NASDAQ
Shares Outstanding 20.34M
Market Cap 334.47M
P/E Ratio 91.33
Div & Yield N.A. (N.A)

Latest News

Market on the Move: Cramer's 'Mad Money' Recap (Friday 10/11/19)

Market on the Move: Cramer's 'Mad Money' Recap (Friday 10/11/19)

Jim Cramer says the market is happy to hear about a possible trade agreement, but without details, it's hard to maintain momentum. Here's your game plan for next week.

Trade Desk, BioLife Solutions, Sage Therapeutics: 'Mad Money' Lightning Round

Trade Desk, BioLife Solutions, Sage Therapeutics: 'Mad Money' Lightning Round

Jim Cramer looks at the Trade Desk, BioLife Solutions, Sage Therapeutics, Iron Mountain, Ventas, Service Corp. International and more.

BioLife Solutions Announces Cell And Gene Therapy Bioproduction Innovation Accelerator

BioLife Solutions Announces Cell And Gene Therapy Bioproduction Innovation Accelerator

BioLife's strategic acquisition strategy expanded to include co-investment with Casdin Capital to boost early stage company development and commercialization

BioLife Solutions Announces New Evo® Cold Chain Customers

BioLife Solutions Announces New Evo® Cold Chain Customers

Leading Cell and Gene Therapy Companies are De-Risking Clinical Trial and Commercial Shipments by Using State of the Art Cloud-Connected Shippers and evo.is

Mustang Bio Adopts CryoStor® Freeze Media And Evo® Cold Chain System For Cell And Gene Therapy Manufacturing And Distribution

Mustang Bio Adopts CryoStor® Freeze Media And Evo® Cold Chain System For Cell And Gene Therapy Manufacturing And Distribution

Pipeline and Clinical Trials Focused on Cancers and Genetic Disorders

BioLife Solutions Announces Second Quarter 2019 Financial Results

BioLife Solutions Announces Second Quarter 2019 Financial Results

- Record quarterly revenue of $6.7 million, up 29% over the prior year

BioLife Solutions Completes Acquisition Of SAVSU Technologies

BioLife Solutions Completes Acquisition Of SAVSU Technologies

evo® Cold Chain Management System, Designed for High-Value, Temperature-Sensitive Biologics, Used for Initial Shipments by 50 Cell & Gene Therapy Companies

BioLife Solutions To Report Second Quarter 2019 Financial Results And Provide Business Update On August 8, 2019

BioLife Solutions To Report Second Quarter 2019 Financial Results And Provide Business Update On August 8, 2019

BOTHELL, Wash., July 31, 2019 /PRNewswire/ --  BioLife Solutions, Inc.

SAVSU Technologies Expands IP Portfolio With Risk Mitigation Technologies For Shipping Cell And Gene Therapies

SAVSU Technologies Expands IP Portfolio With Risk Mitigation Technologies For Shipping Cell And Gene Therapies

Reduced in-transit shipping damage, Extended dynamic thermal performance and Predictive Analytics in Next Generation Dry Vapor Liquid Nitrogen Shippers

SAVSU Technologies Partners With United Cargo® To Improve Cold Chain Management And Delivery Of Cell And Gene Therapies

SAVSU Technologies Partners With United Cargo® To Improve Cold Chain Management And Delivery Of Cell And Gene Therapies

evo® Cold Chain Management System and LifeGuard Same Day Service Reduce Risks for High-Value, Temperature-Sensitive Biologic Drugs

BioLife Solutions To Acquire SAVSU Technologies

BioLife Solutions To Acquire SAVSU Technologies

Acquisition further strengthens portfolio of best in class, proprietary enabling solutions for cell and gene therapy companies

BLFS Crosses Below Key Moving Average Level

BLFS Crosses Below Key Moving Average Level

In trading on Tuesday, shares of Biolife Solutions Inc crossed below their 200 day moving average of $15.33, changing hands as low as $15.06 per share. Biolife Solutions Inc shares are currently trading down about 7.1% on the day.

BioLife Solutions To Join Russell 3000® Index

BioLife Solutions To Join Russell 3000® Index

BOTHELL, Wash., June 10, 2019 /PRNewswire/ --   BioLife Solutions , Inc.

BioLife Solutions To Present At The Jefferies 2019 Healthcare Conference

BioLife Solutions To Present At The Jefferies 2019 Healthcare Conference

BOTHELL, Wash., May 30, 2019 /PRNewswire/ --  BioLife Solutions , Inc.

BioLife Solutions Announces SAVSU Technologies Selected By Novartis To Supply Advanced Cold Chain Management Platform For Newly Approved Gene Therapy

BioLife Solutions Announces SAVSU Technologies Selected By Novartis To Supply Advanced Cold Chain Management Platform For Newly Approved Gene Therapy

Cloud-Connected, Smart Shippers and evo.is Real-Time Visibility Platform Improve Quality of Transportation and Delivery of Lifesaving Therapies

BioLife Solutions Announces First Quarter 2019 Financial Results

BioLife Solutions Announces First Quarter 2019 Financial Results

- Revenue Increased 51% to a Record $5.8 million

BioLife Solutions To Report First Quarter 2019 Financial Results And Provide Business Update On May 9, 2019

BioLife Solutions To Report First Quarter 2019 Financial Results And Provide Business Update On May 9, 2019

BOTHELL, Wash., May 2, 2019 /PRNewswire/ --  BioLife Solutions, Inc.

Biolife Solutions Reaches Analyst Target Price

Biolife Solutions Reaches Analyst Target Price

In recent trading, shares of Biolife Solutions Inc have crossed above the average analyst 12-month target price of $20.00, changing hands for $20.51/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Bullish Two Hundred Day Moving Average Cross - BLFS

Bullish Two Hundred Day Moving Average Cross - BLFS

In trading on Thursday, shares of Biolife Solutions Inc crossed above their 200 day moving average of $13.81, changing hands as high as $14.36 per share. Biolife Solutions Inc shares are currently trading up about 8.5% on the day.

Biolife Solutions Breaks Above 200-Day Moving Average - Bullish For BLFS

Biolife Solutions Breaks Above 200-Day Moving Average - Bullish For BLFS

In trading on Monday, shares of Biolife Solutions Inc crossed above their 200 day moving average of $13.26, changing hands as high as $13.52 per share. Biolife Solutions Inc shares are currently trading up about 11.5% on the day.

Biolife Solutions Enters Oversold Territory (BLFS)

Biolife Solutions Enters Oversold Territory (BLFS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BLFS, BOSC, HESM, PLAB, PSEC Downgrades: CREE, IMMU Initiations: FPH, RNGR Read on to get TheStreet Quant Ratings' detailed report:

Biolife Solutions Reaches Analyst Target Price

Biolife Solutions Reaches Analyst Target Price

In recent trading, shares of Biolife Solutions Inc have crossed above the average analyst 12-month target price of $20.00, changing hands for $20.81/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

BLFS Crosses Above Average Analyst Target

BLFS Crosses Above Average Analyst Target

In recent trading, shares of Biolife Solutions Inc have crossed above the average analyst 12-month target price of $11.50, changing hands for $14.99/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Biolife Solutions Reaches Analyst Target Price

Biolife Solutions Reaches Analyst Target Price

In recent trading, shares of Biolife Solutions Inc have crossed above the average analyst 12-month target price of $10.67, changing hands for $10.71/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Biolife Solutions Reaches Analyst Target Price

Biolife Solutions Reaches Analyst Target Price

In recent trading, shares of Biolife Solutions Inc have crossed above the average analyst 12-month target price of $5.75, changing hands for $5.81/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

TheStreet Quant Rating: C (Hold)